Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2214 in Early Alzheimer's Disease (Phase 2 randomized, placebo-controlled study)
2024-519190-19-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-2214 arm with Placebo arm (2 arms). Primary endpoints: Change from Baseline in Tau PET SUVr, Number of Participants With One or More Adverse Events and 1 more. Planned start Sep 2025; status: authorised.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-519190-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519190-19-00.